Actively Recruiting
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Led by Atea Pharmaceuticals, Inc. · Updated on 2026-04-13
32
Participants Needed
3
Research Sites
72 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
CONDITIONS
Official Title
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to use acceptable contraceptive methods through at least 90 days after last dose of study drug
- Minimum body weight of 50 kg and body mass index (BMI) between 18 and 32 kg/m2
- Willing to comply with study requirements and provide written informed consent
You will not qualify if you...
- Infection with hepatitis B virus, hepatitis C virus, or HIV
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days prior to Day -5
- Use of prescription medications or systemic over-the-counter medications other than assigned methadone or buprenorphine/naloxone maintenance therapy
- Presence of other clinically significant medical conditions or laboratory abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Atea Study Site
Hollywood, Florida, United States, 33019
Actively Recruiting
2
Atea Study Site
Overland Park, Kansas, United States, 66212
Actively Recruiting
3
Atea Study Site
Marlton, New Jersey, United States, 08053
Actively Recruiting
Research Team
A
Atea Study Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here